A groundbreaking investigation spearheaded by researchers at the University of California, San Francisco (UCSF) has illuminated a critical biological mechanism that may elucidate how regular physical exertion enhances cognitive functions, including memory and general thinking abilities. This research posits that engaging in exercise fortifies the brain’s inherent protective mechanisms, thereby shielding it from the detrimental effects of aging-related deterioration.
With advancing age, the integrity of the blood-brain barrier (BBB), a sophisticated and tightly regulated network of blood vessels that acts as a crucial shield for the brain against potentially harmful substances circulating in the bloodstream, undergoes a gradual decline. This specialized barrier, designed to maintain a delicate internal environment for the brain, can become compromised over time, exhibiting increased permeability. Such leakiness permits the ingress of damaging compounds into sensitive brain tissue, triggering inflammatory responses. Neuroinflammation is increasingly recognized as a significant contributor to cognitive decline and is a hallmark feature of neurodegenerative conditions, most notably Alzheimer’s disease.
Several years prior, the same UCSF research collective had made a significant observation: physically active mice exhibited elevated levels of a specific enzyme, identified as GPLD1, within their livers. While this enzyme appeared to promote brain rejuvenation, a perplexing question remained: how did GPLD1, which is incapable of directly crossing the BBB, exert its beneficial effects on cognitive function? This initial discovery left a gap in understanding the precise mode of action.
The latest research endeavors have successfully bridged this knowledge gap, providing a compelling explanation for GPLD1’s neuroprotective capabilities. The scientific team has meticulously detailed how GPLD1 intervenes in the aging process to preserve brain health.
The Mechanism: How GPLD1 Mitigates Neuroinflammation
The core finding of this new study reveals that GPLD1 plays a pivotal role in modulating the activity of another protein, known as TNAP (tissue-nonspecific alkaline phosphatase). As mammalian organisms, including mice, age, TNAP tends to accumulate on the surface of the cells that constitute the blood-brain barrier. This accumulation has been identified as a primary driver of BBB weakening and increased leakiness. Conversely, when mice engage in regular exercise, their livers respond by releasing GPLD1 into the systemic circulation. This circulating GPLD1 then travels to the vascular network surrounding the brain, where it effectively targets and removes TNAP from the surface of BBB-forming cells. This targeted removal process is instrumental in restoring the structural integrity and functional impermeability of the blood-brain barrier.
"This discovery underscores the profound interconnectedness between systemic bodily functions and the aging process of the brain," remarked Saul Villeda, PhD, an associate director at the UCSF Bakar Aging Research Institute and a senior author of the study. He emphasized the significance of looking beyond the brain itself to understand age-related cognitive decline.
The comprehensive findings of this research were formally published in the esteemed scientific journal Cell on February 18th.
Unraveling TNAP’s Specific Contribution to Cognitive Impairment
To precisely ascertain the pathways through which GPLD1 exerts its salutary effects, the researchers meticulously focused on the known enzymatic capabilities of GPLD1. GPLD1 is characterized by its ability to cleave specific protein structures from the outer membranes of cells. With this understanding, the scientists embarked on a systematic search for cellular tissues that might harbor proteins susceptible to GPLD1’s action, hypothesizing that certain proteins might accumulate with advancing age.
The cells forming the blood-brain barrier emerged as particularly promising candidates, as they were found to express several proteins that could potentially serve as targets for GPLD1. Through rigorous laboratory testing, the researchers identified a single protein that was demonstrably cleaved by GPLD1: TNAP.
Subsequent experimental validations further cemented the critical importance of TNAP in the context of cognitive decline. In experiments involving young mice that were genetically engineered to overexpress TNAP within their blood-brain barrier cells, the animals exhibited memory deficits and cognitive impairments strikingly similar to those observed in much older, naturally aging rodents.
Crucially, when the researchers intervened by reducing TNAP levels in 2-year-old mice – a physiological age equivalent to approximately 70 human years – they observed a significant restoration of BBB function. The barrier became less permeable, indicating a reduction in leakiness. Concurrently, levels of neuroinflammation decreased, and these older mice demonstrated improved performance on a battery of memory and cognitive tests.
"The fact that we were able to access and effectively utilize this biological mechanism even in the later stages of life, in the context of these mouse models, and achieve positive results, is highly encouraging," stated Gregor Bieri, PhD, a postdoctoral scholar within Dr. Villeda’s laboratory and a co-first author of the groundbreaking study.
Profound Implications for Alzheimer’s Disease and Brain Aging
The implications of these findings are far-reaching, suggesting novel therapeutic avenues for addressing age-related cognitive decline and neurodegenerative diseases like Alzheimer’s. Specifically, the research points towards the potential development of pharmaceutical interventions designed to target and cleave proteins such as TNAP. Such therapies could offer a promising strategy for restoring the compromised blood-brain barrier, even in individuals whose BBB has already been significantly weakened by the aging process.
"We are uncovering fundamental biological processes that have historically been overlooked in much of the Alzheimer’s research," Dr. Villeda commented, highlighting the potential paradigm shift his team’s work represents. "This could open up entirely new therapeutic possibilities that move beyond the conventional strategies, which have largely focused exclusively on interventions directly within the brain."
The study involved a collaborative effort with numerous UCSF researchers, including Karishma Pratt, PhD; Yasuhiro Fuseya, MD, PhD; Turan Aghayev, MD; Juliana Sucharov; Alana Horowitz, PhD; Amber Philp, PhD; Karla Fonseca-Valencia, degree; Rebecca Chu; Mason Phan; Laura Remesal, PhD; Andrew Yang, PhD; and Kaitlin Casaletto, PhD. A complete list of authors and their affiliations is available in the published paper.
This significant research was supported by grants and funding from various esteemed institutions, including the National Institutes of Health (grant numbers AG081038, AG086042, AG082414, AG077770, AG067740), the Simons Foundation, the Bakar Family Foundation, the Cure Alzheimer’s Fund, the Hillblom Foundation, the Glenn Foundation, the Japan Society for the Promotion of Science (JSPS), a Japanese Biochemistry Postdoctoral Fellowship, the Multiple Sclerosis Foundation, Frontiers in Medical Research, the American Federation for Aging Research, the National Science Foundation, the Bakar Aging Research Institute, and Marc and Lynne Benioff.
About the Author
